Loading…
Employees: 192
Size Genfit (GNFT.PA) is a France Health Care company (Biotechnology) with a market value of $593M, the 165th largest of 206 France companies the cockpit tracks. Shares closed at €10.60 on 6 Nov 2026.
Performance Over six months the shares gained 19.4%, against -15.5% for the median peer and -0.4% for the France market (cap-weighted) — 2nd highest of 18 in its peer set.
Growth Revenue grew 27.7% over the last twelve months (peer median +6.2%); the operating margin is -130.4% (peer median -10.8%).
Valuation It trades at 79.3× forward earnings against a peer median of 19.2× (2nd most expensive of 6).
Price implies For today's price to make sense, revenue must grow about 40% a year for seven years (Req g). Recent delivered growth is +143%, so the hurdle is -103 pp: the price already allows for a slowdown.
Next results Next results expected around 8 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €53.0M | €65.4M | €67.0M | €28.6M | €20.2M |
| Revenue growth | — | -2% | +135% | +41% | — |
| Gross profit | €1.01M | €14.6M | €65.3M | n/a | n/a |
| EBITDA | -€17.1M | -€8.04M | €1.39M | -€34.9M | -€31.2M |
| Net income | -€102M | -€86.0M | €1.51M | -€28.9M | -€23.7M |
| Free cash flow | €7.50M | -€26.7M | €14.2M | -€56.3M | -€74.7M |
| Capital expenditure | €914,000 | €3.42M | €979,000 | €2.49M | €0 |
| Total debt | n/a | €151M | €62.1M | €70.2M | €75.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GNFT.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +27.2% | -15.9% | highest of 21 |
| 6-month return | +19.4% | -15.5% | 2nd highest of 18 |
| Distance from 52-week high | -31.5% | -47.7% | 5th highest of 21 |
| Revenue growth (TTM) | +27.7% | +6.2% | 6th highest of 16 |
| Operating margin | -130.4% | -10.8% | 7th lowest of 16 |
| Forward P/E | 79.3× | 19.2× | 2nd most expensive of 6 |
| Growth the price implies (Req g, 7 yrs) | 40.0% | 31.6% | most demanding of 4 |
| Growth delivered (Del g) | +143.5% | +7.0% | highest of 4 |
| Hurdle (Req g minus delivered) | -103.4 pp | +8.2 pp | least demanding of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Genfit GNFT.PA | France | $593M | +19% | +28% | -130% | 79.3× | 40.0% | +143.5% |
| Climb Bio CLYM | United States | $591M | -10% | n/a | n/a | n/a | n/a | n/a |
| Ascletis Pharma 1672.HK | Hong Kong | $610M | -73% | -59% | -71,976% | n/a | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $576M | n/a | +674% | -495% | n/a | n/a | n/a |
| Faeth Therapeutics FTH | United States | $570M | -6% | n/a | n/a | n/a | n/a | n/a |
| Apnimed APMD | United States | $629M | n/a | +380% | -140% | n/a | n/a | n/a |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $554M | n/a | n/a | n/a | n/a | n/a | n/a |
| Geron GERN | United States | $636M | -29% | +19% | -8% | 16.7× | n/a | n/a |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $553M | -19% | +6% | -11% | n/a | n/a | n/a |
| Design Therapeutics DSGN | United States | $639M | -28% | n/a | n/a | n/a | n/a | n/a |
| Kura Oncology KURA | United States | $647M | -23% | -7% | -412% | n/a | n/a | n/a |
| Getein Biotech 603387.SS | China | $647M | -12% | +8% | 21% | n/a | -8.3% | -1.3% |
| Sinotherapeutics 688247.SS | China | $537M | -14% | -17% | 0% | n/a | 31.6% | +7.0% |
| Valneva VLA.PA | France | $534M | -2% | -27% | -87% | n/a | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $531M | -33% | +2% | 17% | 11.2× | n/a | n/a |
| Wave Life Sciences WVE | United States | $664M | -53% | -35% | -321% | n/a | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $664M | +7% | +32% | 4% | 82.0× | 35.4% | +27.2% |
| Liaoning Dingjide Petrochemical 603255.SS | China | $530M | -15% | +70% | 5% | 19.2× | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $526M | -25% | +4% | 8% | 22.6× | n/a | n/a |
| Candel Therapeutics CADL | United States | $670M | +5% | n/a | n/a | n/a | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $677M | +21% | +278,712% | -214% | n/a | n/a | n/a |